Blueprint Medicines (BPMC) Misses Q3 EPS by 37c
Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.00), $0.37 worse than the analyst estimate of ($1.63).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.00), $0.37 worse than the analyst estimate of ($1.63).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.